Telix Pharmaceuticals Limited, an Australia-based therapeutic and diagnostic radiopharmaceuticals company listed on NASDAQ under the ticker TLX, released its full fiscal year 2025 revenue figures on Tuesday, highlighting significant growth in several business areas alongside ongoing stock price volatility.
The company reported annual revenue of about $804 million, which meets its previously raised forecast range of $800 million to $820 million. This result underscores Telix's ability to achieve its financial objectives despite a complex market environment.
The fourth quarter alone saw revenues reach approximately $208 million, marking a substantial 46% increase compared to the same quarter in the previous year. Such growth demonstrates accelerating business momentum as the year concluded.
Within the Precision Medicine division, quarterly revenue reached near $161 million, reflecting a 4% sequential increase. This uptick was largely attributed to the recent successful launch of Gozellix in the United States, following its reimbursement approval by the Centers for Medicare and Medicaid Services (CMS) that became effective October 1, 2025. This development has positively impacted the company’s diagnostic product utilization and revenue streams.
Telix continues to advance its clinical pipeline, with ongoing international patient enrollment in the ProstACT Global Phase 3 study as well as the SOLACE Phase 1 study in the U.S. last week marked a milestone with the dosing of the first patient in the U.S. for the BiPASS Phase 3 trial. This trial evaluates Telix’s commercial prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging agents—Illuccix and Gozellix—in the initial diagnosis setting of prostate cancer, reinforcing the company’s commitment to expanding its radiopharmaceutical diagnostic capabilities.
Strategic collaboration efforts also progressed, notably with Varian, a Siemens Healthineers company. This partnership aims to explore integrating Telix’s radiopharmaceuticals with external beam radiation therapy, potentially enhancing treatment efficacy through combination approaches.
Despite these operational positives, Telix’s stock performance has faced headwinds. Shares have declined approximately 56.91% over the past twelve months, positioning the stock closer to its 52-week lows than highs. Technical indicators underscore this bearish trend: the stock is trading 5.5% below its 20-day simple moving average (SMA) and 22.6% below the 100-day SMA, typically a sign of sustained short- to medium-term weakness.
The relative strength index (RSI) currently stands at 41.91, indicating a near-neutral stance between overbought and oversold conditions, suggesting neither buying nor selling pressures dominate. Meanwhile, the moving average convergence divergence (MACD) is above its signal line, pointing to potential short-term bullish momentum within an otherwise challenging market context. Together, these indicators suggest mixed signals in investor sentiment for the stock.
Key technical price levels for Telix stock include a resistance at $8 and a support level of $7, which may represent critical thresholds for future trading activity.
From an analyst perspective, there remains general optimism despite recent stock underperformance. The consensus recommendation for TLX remains a Buy rating, with an average price target of $21.20 indicating substantial upside potential relative to the current trading price. Notable firms maintaining buy recommendations include HC Wainwright & Co., which set a $20 target as of January 21, and UBS, which also set its target at $20, albeit with a lowered projection as of September 23, 2025.
William Blair analyst Andy Hsieh recently emphasized Telix's transition from predominantly a diagnostics-focused entity to a radiopharmaceutical company centered on theranostics—a combined diagnostic and therapeutic approach. Hsieh’s Outperform rating reflects expectations that products like Illuccix and Gozellix can provide durable and expanding cash flows to underpin this strategic evolution.
Analytically, Telix trades at a premium price-to-earnings (P/E) multiple relative to peers, but strong consensus for approximately 15% earnings growth appears to justify the valuation in the eyes of market analysts, supporting a projected 194% increase relative to current analyst price targets.
The Benzinga Edge scorecard highlights Telix’s current challenges: momentum scores very low at 1.84 out of 100, indicating significant underperformance against broader market benchmarks. Its value score of 6.41 out of 100 suggests the stock is seen as trading at a steep premium when compared to comparable companies.
In summary, while Telix Pharmaceuticals demonstrates robust revenue growth and clinical progress indicative of effective management and operational execution, its stock price faces considerable downward pressure. Factors such as the premium valuation, disappointing momentum, and overall market skepticism continue to weigh on investor sentiment, affirming ongoing risk for prospective shareholders.
At the time of this report, TLX shares were trading down 6.86% at $7.20, reflecting immediate market reactions amid the company’s detailed financial disclosures and clinical development announcements.